Ovarian cancer cells with CD44+/CD24-, CD133, or ALDH show higher likelihood of recurrence, resistance to standard chemotherapy and radiotherapy, and poor prognosis (Meng et al., 2012, Zhang et al., 2012, Stemberger-Papic et al., 2015, Landen et al., 2010). Here, CD44 is linked to ovarian carcinoma.